Lexology February 18, 2021
Nossaman LLP

Congress and the Biden Administration are grappling with an economic stimulus bill that will touch many segments of American life, including health care, if it passes in the Senate. This has many clients wondering what impact the Biden Administration will have on the healthcare sector from a regulatory perspective. Early indications point to a focus on four issues that continue to resound: the Affordable Care Act (“ACA”), COVID-19-related regulatory relief, lowering prescription drug prices and restricting the occurrence of surprise billing.

The ACA

To strengthen the ACA, the Biden Administration has proposed three key steps: (1) capping the amount each household spends on insurance premiums at 8.5% of household income; (2) increasing subsidies to low-income Americans; and (3) initiating an...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: ACA (Affordable Care Act), Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Insurance, Medicaid, Payer, Pharma, Pharma / Biotech, Pricing / Spending, Public Exchange, Public Health / COVID
Related Articles:
Congressional spending plan: What’s in it for healthcare, and what isn’t
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Another House bill aims to protect against hospital cyberattacks
A health care earthquake in Congress

Share This Article